– SNA-001 addresses a large unmet need in laser hair removal by treating light hair using a topical solutionof silver photoparticles, an ultra-efficient light absorber – – If cleared, SNA-001 has potential to expand the $3 billion U.S. laser hair removal market as an effective option for light-haired consumers – – Sienna to seek strategic partner for SNA-001, and will continue to focus on Phase 3 development of SNA-120 for Psoriasis and Pruritus and its Topical by Design™ Platform – WESTLAKE VILLAGE, Calif., Feb. 08, 2019 (GLOBE NEWSWIRE) — Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage biotechnology company, today announced positive topline results from its pivotal trial of SNA-001 in conjunction with an 810 nm Diode laser, involving 65 patients. SNA-001, a topical pre-treatment to standard laser hair removal, was studied in women and men with white, gray, blonde, light red and light brown hair. The data showed SNA-001 met the primary endpoint of non-inferiority in hair reduction (-17.5 percent with SNA-001+Laser compared to -1.1 percent with vehicle+Laser following six treatment sessions). In additional analyses, SNA-0...